Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 612 participants.

Also called NCT02480764

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 612 participants (enrolled count) (from the registry)
Sponsor
  • Takeda Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02480764
  • WHO UTN U1111-1159-5579
Other papers using this trial's data
  • A phase 3 double-blind randomized (CONSORT-compliant) study of azilsartan medoxomil compared to valsartan in Chinese patients with essential hypertension Medicine, 2020-08-07 DOI, PubMed 32769878, PMC7505320 PubMed links an erratum for this paper. Erratum: PMID 32899104 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02480764. Randomized; quadruple masking; primary purpose treatment. Start 2015-08-27 (actual); primary completion 2017-09-22 (actual). Results posted on 2019-02-11.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension
Condition
Essential Hypertension
Intervention (Drug)
Azilsartan medoxomil
Intervention (Drug)
Valsartan
Intervention (Drug)
Azilsartan medoxomil Placebo
Intervention (Drug)
Valsartan Placebo
Lead sponsor
Takeda (class: industry)

Record details

Record id
cardio:ct-nct02480764
Content hash
4ad710f6411d45f9896a8c44572ff232a595aa4d3ab7ae412131caa388e76a25